Table 1.
Patient characteristics and treatments
| Number | Percent | |
|---|---|---|
| Patients | 71 | |
| Age (years) | ||
| Median | 70 | (range 47–84) |
| Sex | ||
| Male | 57 | 80.3 |
| Female | 14 | 19.7 |
| Performance status | ||
| 0 | 57 | 80.3 |
| ≥ 1 | 14 | 19.7 |
| Observation period (months) | ||
| Median | 43.6 | (range 1.5–124.2) |
| Main tumor location | ||
| Upper thoracic | 12 | 16.9 |
| Middle thoracic | 41 | 57.7 |
| Lower thoracic | 18 | 25.4 |
| Depth of tumor invasion | ||
| Muscularis mucosa | 6 | 8.5 |
| Submucosa | 65 | 91.5 |
| Tumor length (cm) | ||
| Median | 4.0 | (range 1–30) |
| Circumferential spread of tumor | ||
| Median | 0.50 | (range 0.17–1) |
| Tumor number | ||
| 1 | 65 | 91.5 |
| ≥ 2 | 6 | 8.5 |
| Treatment | ||
| RT | 18 | 25.4 |
| CRT | 8 | 11.3 |
| ER + RT (ESD/EMR) | 6 (4/2) | 8.5 |
| ER + CRT (ESD/EMR) | 39 (38/1) | 54.9 |
| RT field | ||
| Non-ENI | 32 | 45.1 |
| ENI | 39 | 55.0 |
| Radiation dose (Gy) | ||
| Median | 50.4 | (range 28–68) |
| Chemotherapy | ||
| Standard dose FP (2 cycles) | 35 | 74.5 |
| Low-dose FP (2 cycles) | 6 | 12.8 |
| Others | 6 | 12.8 |
CRT chemoradiotherapy, EMR endoscopic mucosal resection, ENI elective nodal irradiation, ER endoscopic resection, ESD endoscopic submucosal dissection, FP 5FU + Cisplatin, RT radiotherapy